By Herman F. Bozenhardt and Erich H. Bozenhardt,Integrated Project Services (IPS)
In part 1 of our article on biocontainment, we discussed the history of biocontainment as an outgrowth of medical research, especially the effort to develop vaccines for various worldwide diseases. We provided some definition of the biosafety levels (BSLs) established by the Centers for Disease Control and Prevention (CDC) based on risk considerations. We also discussed the regulatory regime for biological agents and, specifically, for designing a facility for an FDA- or EU-regulated product within the confines of the safety practices dictated by the CDC and design requirements of the NIH.
The ability to interrogate protein phosphorylation events and aberrant phosphorylation levels is critical to our understanding of various biological and pathological processes, particularly in the research of diseases, such as cancer. However, detection of phosphorylated proteins in western blots can be challenging. Following are ten tips to ensure robust data generation and cleaner blots.
Revolutionize your cell, gene and CAR-T clinical and late stage programs by attending this year’s Cell & Gene Therapy Bioprocessing & Commercialization meeting, held September 9-12, 2019 in Boston. Register your team today to learn and network with 400+ of the brightest minds working in cell & gene therapies. Book online with code CELLGENE by August 30 to save an extra 10% (new registrations only). To view the full agenda and to register, visit here.